Trial · NCT06271057
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
NCT06271057, Phase 2, Recruiting, The Lymphoma Academic Research Organisation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse. Trials, record NCT06271057. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06271057
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
- NCT number
- NCT06271057
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 65 participants, estimated
- Lead sponsor
- The Lymphoma Academic Research Organisation
- Conditions
- Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma
- Interventions
- golcadomide
- First posted
- 2024-02-21
- Last updated
- 2026-06-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete metabolic response rate (CMR rate) | 3 months | efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion |
| Secondary | Objective response rate (ORR) | at 1 month, 3 months, 6 months, 1 year and 2 years, from CAR-T infusion | incidence of either a complete (CMR) or a partial (PMR) metabolic response per the Lugano Classification (Cheson 2014) as determined by study investigators |
| Secondary | Objective response rate (ORR) | at 1 month and 3 months | determined by imaging central review |
| Secondary | Complete response rate (CRR) | at 1 Month, 6 Months, 1 year, and 2 years | percentage of complete response determined by investigator assessment classification |
| Secondary | Duration of response (DR) | 2 years | time from attainment of PMR or CMR to the date of first documented disease progression/relapse (based on investigator disease assessment (INV)) or death from any cause |
| Secondary | Event-free survival (EFS) | 2 years | the time between CAR T-cells injection and death, disease progression, or start of subsequent new anti-lymphoma therapy including Stem Cell Transplant (SCT) |
| Secondary | Progression-free survival (PFS) | 2 years | time from CAR T-cells injection to the first observation of documented disease progression/relapse (based on investigator disease assessment (INV)) or death |
| Secondary | Time To Next anti-Lymphoma Treatment (TTNLT) | 2 years | from the date of CAR T-cells injection to the date of first documented administration of any new anti-lymphoma treatment |
| Secondary | Overall survival (OS) | 2 years | from date of CAR T-cells injection to the date of death |
| Secondary | Incidence of Adverse Events and Serious Adverse events | 2 years |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06271057
GET https://conductscience.org/api/trials/v1/NCT06271057/registered